Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis.
Combination immunotherapy has become an actively growing field of clinical investigation. We searched for clinical trials of combination immunotherapy and calculated the pooled hazard ratio (HR), odds ratio (OR) of clinical outcomes and safety by subgroups of different combination regimens. Totally 28 clinical trials were analyzed. The study showed that the pooled HRs of overall survival and progression-free survival for combination therapy were 0.77 (95% CI: 0.70-0.84, p < 0.001) and 0.72 (95% CI: 0.66-0.79, p < 0.001) while the pooled OR of high-grade adverse effects was 1.45 (p = 0.004). Subgroup analysis showed that the HR of overal survival were 0.74 (p = 0.005), 0.79 (p < 0.001), 0.70 (p = 0.003) and 0.85 (p = 0.052) for immunotherapy combined with immunotherapy, chemotherapy, targeted therapy and radiotherapy group, respectively. The meta-analysis indicated that combination immunotherapy could bring more clinical benefits with increased high-grade adverse effects.